Bernhardt G Zeiher has bought stock on 2 days since Mar 2025

Bernhardt G. Zeiher, M.D., FCCP, FACP, is a pharmaceutical executive and physician who serves as a director on the board of Entrada Therapeutics, Inc. (NASDAQ: TRDA), where he has recently been reported as trading company stock in his capacity as a corporate insider.( He also sits on the boards of Amylyx Pharmaceuticals and Abeona Therapeutics, contributing his extensive experience in drug development and clinical strategy across multiple innovative biotech companies.(

Zeiher previously served as Chief Medical Officer at Astellas Pharma from 2018 to 2022, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance, and oversaw the approval of 15 new treatments addressing serious diseases with significant unmet need.( Before becoming CMO, he spent more than a decade at Astellas in roles of increasing responsibility and earlier in his career practiced internal medicine at a tertiary medical center in Indianapolis.( He has held board or advisory roles with organizations such as the PhRMA Biomedical Advisory Committee, TransCelerate Biopharma, the Biotechnology Innovation Organization, and the Astellas Global Health Foundation.( Zeiher earned a B.S. in biology from the University of Toledo and a Doctor of Medicine from Case Western Reserve University School of Medicine, followed by an internal medicine residency at University Hospitals of Cleveland.(

Written by Perplexity from public sources.